Will Tirzepatide Get Cheaper in India? Mounjaro's Patent, Generic Timeline, and What Actually Moves the Price

In March 2026, semaglutide went from ₹5,660 a month at the cheapest branded dose to ₹1,300 a month for a Natco vial in the space of a few weeks. Everyone on tirzepatide, which costs ₹13,000 to ₹26,000 a month, watched that happen and asked the obvious question. This article answers it honestly, in three parts: the patent, the things that can move the price before the patent, and what you can do about your own cost now.

Part 1: the patent, and why it is not like semaglutide's

Semaglutide's Indian patent was old. Novo Nordisk filed it in the mid-2000s, so its 20-year term ran out in March 2026 and Indian manufacturers had years to prepare. Tirzepatide is a much newer molecule: Eli Lilly's Indian patent filings were granted with decisions recorded in 2025, and the compound protection runs to 2036. There is no approved generic tirzepatide anywhere in the world, and the peptide is more complex to make than semaglutide, which raises the bar for anyone trying.

Could an Indian company challenge the patent? Yes, and Indian generics firms have a long record of doing exactly that, sometimes successfully. But a challenge takes years, the outcome is uncertain, and the earliest realistic generic entry even in the US, where challenges are furthest along, is being estimated at 2028 to the early 2030s. For planning purposes, assume no generic tirzepatide in India before 2030 at the earliest, and quite possibly not before 2036.

Part 2: what can move the price before 2036

Lilly cuts the price itself

This is the most likely lever. Novo cut Wegovy's Indian price by 37% in December 2025, before its patent even expired, because it could see the generics coming. Lilly faces no generic, but it does face something almost as effective: generic semaglutide at a fifth of the price, taking share every month. When a doctor can put a BMI-31 patient on Semasize for ₹2,500, Mounjaro at ₹16,000 has to justify the gap on results alone. Lilly's answer in other markets has been vial formats and direct-to-patient pricing; expect something similar here as the share loss continues.

Co-marketing and volume

Yurpeak, Cipla's co-marketed tirzepatide, exists to reach the pharmacies and small cities Lilly's own sales force does not. More volume means more room to cut. Watch Yurpeak's price rather than Mounjaro's; if the two ever diverge, the cheaper one is the signal.

A cheaper strong option arrives

Orforglipron, Lilly's own daily tablet, is coming to India, and retatrutide, Lilly's triple-agonist injection, is in late trials. Both give Lilly reasons to reposition tirzepatide's price within its own range. And generic semaglutide is not standing still; the Indian brands are already competing with each other on price, and the floor keeps moving down.

Government price control

India's NPPA caps prices on essential medicines. GLP-1s are not on the National List of Essential Medicines, and adding a patented weight-loss drug would be an unusual step. Do not plan around it.

Part 3: lowering your own tirzepatide cost now

• Do not run up the dose for its own sake. Most people get the bulk of their result at 5 to 10 mg; 15 mg costs almost twice what 5 mg does. A doctor who holds you at the lowest effective dose saves more money than any price cut will.
• Start on semaglutide if your BMI is under 35. The head-to-head difference is about six percentage points. For many people, semaglutide at ₹2,500 a month gets them to goal, and tirzepatide is there if it does not. See the decision guide.
• Lose on tirzepatide, hold on semaglutide. Maintenance needs less drug than loss. Moving to generic semaglutide once you are at goal is a common, doctor-managed pattern that cuts the monthly bill by 80%.
• Buy the plan, not the pen. ALTRcare's tirzepatide plan is ₹34,999 for three months with the doctor, delivery and reviews included; at pharmacy prices the pens alone across a typical titration cost more than that. The cost calculator shows the comparison for your dose.
• Avoid grey-market "generic tirzepatide". It does not exist as a licensed product. Anything sold under that name is unlicensed, and there is no way to know what is in it.